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Available online 25 April 2018Somatic mutations contribute to the heterogeneous prognosis of chronic myelomonocytic leukemia (CMML).
Hypomethylating agents (HMAs) are active in CMML, but analyses of small series failed to identify mutations
predicting response or survival. We analyzed a retrospective multi-center cohort of 174 CMML patients treated
with a median of 7 cycles of azacitidine (n=68) or decitabine (n=106). Sequencing data before treatment ini-
tiation were available for all patients, from Sanger (n = 68) or next generation (n = 106) sequencing. Overall
response rate (ORR) was 52%, including complete response (CR) in 28 patients (17%). In multivariate analysis,
ASXL1mutations predicted a lower ORR (Odds Ratio [OR]= 0.85, p=0.037), whereas TET2mut/ASXL1wt genotype
predicted a higher CR rate (OR=1.18, p=0.011) independently of clinical parameters.With amedian follow-up
of 36.7 months, overall survival (OS) was 23.0 months. In multivariate analysis, RUNX1mut (Hazard Ratio [HR] =
2.00, p= .011), CBLmut (HR= 1.90, p=0.03) genotypes and higherWBC (log10(WBC) HR= 2.30, p= .005) in-
dependently predicted worse OS while the TET2mut/ASXL1wt predicted better OS (HR = 0.60, p = 0.05). CMML-
specific scores CPSS and GFM had limited predictive power. Our results stress the need for robust biomarkers
of HMA activity in CMML and for novel treatment strategies in patients with myeloproliferative features and
RUNX1 mutations.






Chronicmyelomonocytic leukemia (CMML) is a clonal bonemarrow
disorder, classified by WHO as a myelodysplastic/myeloproliferativeHôpital Saint-Louis, Assistance




an open access article under theneoplasm (MDS/MPN) [18]. It is characterized by persistent
monocytosis associatedwith a variable degree of bonemarrow blast ex-
cess, cytopenias and myeloproliferation. Its prognosis is variable but
overall poor, with a median survival of 20–32 months and a risk of
acute myeloid leukemia (AML) transformation of 14–29% [8,11].
Recurrent somatic mutations found in CMML affect genes encoding
epigenetic regulators, signaling, splicing and transcription regulator
genes [11,14,16,19]. The high frequency of TET2, ASXL1, SRSF2, and RAS
pathway (NRAS, KRAS, and CBL) mutations may represent a mutational
fingerprint of the disease [11,19]. Frameshift and nonsense ASXL1muta-
tions have invariably been shown to confer poor prognosis [8,11,19],CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[11,13,21] is more controversial, and could depend on specific mutation
combinations. Mutations in EZH2 [9], SETBP1 [8] andDNMT3A [22] could
also be detrimental, but their impact is more difficult to assess because
of their lower incidence. Recently, several prognostic scoring systems
accounting for gene mutations have been developed in CMML, but
most of them were developed in cohorts of untreated patients, or with
heterogeneous treatments [8,11]. The prognostic value of gene muta-
tions is highly dependent on the therapeutic context, as exemplified
by the specific poor prognosis of RASmutations in CMML in the context
of allogeneic stem cell transplantation (ASCT) [30].
Retrospective studies [1,5,23] and limited prospective data [3,6,25],
mostly non-randomized, have reported activity of hypomethylating
agents (HMA) in CMML. In these studies, azacitidine (AZA) and
decitabine (DAC) provided an overall response rate (ORR) of 40–70%,
translating in median overall survivals (OS) of 12–22months. Response
to HMA is difficult to predict and is loosely correlated to survival in
CMML [7]. In MDS patients treated with HMA, mutations in the epige-
netic regulators TET2 [2,10,28] and ASXL1 [2] affect response rates but
not overall survival (OS). In retrospective studies of CMML treated
with HMA, older age, higher bone-marrow (BM) and peripheral blood
(PB) blast count, higher white blood cell counts (WBC), splenomegaly
and cytogenetic risk have been found to impair survival [1].
The impact of gene mutations in this setting has so far been ad-
dressed in small series, precluding the identification of mutations
predicting response or survival in CMML treated with HMA [3,15,25].
Here we report the largest retrospective cohort of CMML patients
treated with DAC or AZA to date with available molecular data for the
most frequently mutated genes.
2. Patients and Methods
2.1. Patients
Weupdated clinical data from 174 patients with CMML treatedwith
AZA or DAC between February 2007 and December 2016, in Groupe
Francophone des Myélodysplasies (GFM) centers (n = 61, including
Dresden), Firenze (n=37), Mayo clinic (n= 41), Memorial Sloan Ket-
tering (MSKCC) and Moffitt (MCC) Cancer Centers (n = 35). Patients
provided written informed consent and the study was approved by
each institution's IRB (GFM: PHRC MAD-06 and clinical trial EudraCT
#2008-000470-21; Mayo clinic: 15-003786 and 11-005599; Firenze
NCT01251627; MCC/MSKCC: 00014416). Patients with previous inten-
sive treatment (intensive chemotherapy or ASCT) orwith AML transfor-
mation prior to HMA were excluded.
CMML diagnosis and stratification was made according to WHO
2008 criteria [18]. Splenomegalywas defined as a clinical or radiological
spleen enlargement. Bonemarrow blasts included agranular blasts, my-
eloblasts and promonocytes as recommended. Cytogenetic risk was
assessed according to CMML-specific cytogenetic risk classification
[27]. Prognosis at initiation of treatment was evaluated according to
CMML-specific prognostic scoring system (CPSS) [27] and GFM score
[11]. Information on RBC-transfusion dependency was not available
and was substituted by hemoglobin level (Hb b 10 g/dL) to calculate
CPSS as proposed by the authors [27]. CPSS-mol [8] was assessed in pa-
tients with either available SETBP1 information, or for whom the risk
was unchanged whatever the SETBP1 mutational status. Patients re-
ceived HMA according to standard schedules (AZA: 75 mg/m2/d subcu-
taneously d1-7/28d cycles; DAC: 20 mg/m2/d intravenous d1-5/28d
cycles). Responses were assessed according to MDS IWG-2006 criteria
[4].
2.2. Gene Mutation Analyses
DNA extracted from peripheral blood (PB) CD14+ monocytes or
bone marrow (BM) mononucleated cells (BMNCs) for GFM centers,BMNCs for Mayo Clinic and Firenze, BMNCs or PB mononucleated cells
(PBMCs) for MSKCC and MCC. Analysis of somatic mutations was
done by Sanger sequencing (GFM) or Next-Generation Sequencing
(NGS), using custom target capture with Agilent SureSelect (Mayo
Clinic), Agilent HaloPlex (Firenze), Fluidigm Access Array multiplex
PCR technologies (MSKCC and MCC) followed by sequencing on
Illumina platforms. The overlapping genomic regions interrogated by
all platforms included exon 12 of ASXL1, and all coding exons in the
SRSF2, TET2, NRAS, RUNX1, CBL, U2AF1, DNMT3A, IDH2, KRAS, SF3B1,
JAK2, EZH2, IDH1 and TP53 genes. Details on mutational analysis pipe-
lines have previously been published [11,15,20,24].
2.3. Statistical Analyses
Variables are reported as medians and interquartile ranges (IQR)
and numbers and proportions for continuous and categorical variables
respectively. Group comparisons for dichotomic, ordinal and continu-
ous variables were carried by Fisher's exact tests, Kendall's correlation
tests, and Mann-Whitney's tests respectively. Univariate analyses of
variables influencing response rates were stratified on HMA and tested
with linear regressions. All significant variables with significant impact
(p b 0.05) in univariate analyses were then included in multivariate lin-
ear regressions adjusted on HMA.
OS was defined as time between initiation of HMA and date of death
from any cause or date of last follow-up. AML free survival (AMLFS)was
defined as the timebetween initiation of HMAanddate of AML transfor-
mation, death or last follow-up. OS and AMLFSwere obtained according
to the Kaplan-Meier method and univariate analyses stratified on HMA
were done with the Cox regression model. Follow-up duration was cal-
culated with the inverse method. The prognostic impact of WBC was
assessedwith the log10-transformed variable (logWBC), and age, hemo-
globin level, platelets count were analyzed as continuous variables.
Multivariate survival analyses were performed by Cox regression
followed by backward stepwise selection. The proportional hazard as-
sumptionwas validated by visual inspection of Schöenfeld residuals. In-
teractions were studied by comparing through a likelihood ratio test
Cox models including the two studied variables with or without an in-
teraction term. The goodness-of-fit of a given model was assessed
with Harrell's C concordance index (C-index), a value ranging from 0.5
(no relevance) to 1 (perfect prediction).
There was no sample size calculation prior to this retrospective
study. In a post hoc power analysis using two-sided log-rank tests
with an alpha risk of 0.05, a study population of 174 patients provided
a power of 0.70 to detect a hazard ratio (HR) of 2.5 or higher for muta-
tions present in only 10% of patients or to detect a milder effect (HR
≥ 1.5) formore frequentmutations (40% of patients). Mutations present
in b10% of patients were thus not analyzed. Thus, only complete cases
were analyzed, with imputation of missing data.
Propensity Score Matching (PSM) was performed by logistic regres-
sion using indicated variables, and patients werematched one to one by
nearest neighbour according to HMA received. Quality of matching was
checked by inspecting the reduction of bias for each variable and testing
for differences in matched samples for each variable. All statistical anal-
yses were stratified on HMA and two-sided, retaining p b 0.05 as statis-
tically significant. Analyseswere performedwith R 3.3.2 (cran.r-project.
org) or STATA 12 (Stata Corp).
3. Results
3.1. Patients Characteristics
We included 174 patients in this study, 118 men (68%) and 56
women (32%) with a median age of 72 years (Inter-quartile range
[IQR] 66–78). Characteristics of patients at initiation of HMA are sum-
marized in Table 1. Diagnosis at HMA onset was CMML-1 and CMML-
2 in 64% and 36% respectively. Cytogenetic risk was low, intermediate,
Table 1
Characteristics of the study population at HMA onset. Median [IQR] or N (%).
Patients Total (n = 174) AZA (n = 68) DAC (n = 106) AZA vs DAC p=a
Gender, male 118 (68%) 45 (66%) 73 (69%) 0.74
Age (years) 72 [66–78] 74 [68–79] 71 [66–77] 0.081
Splenomegaly, yes 67 (40%) 24 (36%) 43 (42%) 0.52
WBC (×109/L) 15.4 [8.6–26.0] 13.3 [7.7–22.8] 17.5 [9.1–28.1] 0.041
Hb (g/dL) 9.8 [8.7–11.8] 9.7 [8.7–11.2] 10.1 [8.6–11.9] 0.52
ANC (×109/L) 7.6 [3.6–13.9] 5.7 [3.3–12.5] 8.7 [3.8–15.5] 0.078
Platelets (×109/L) 84 [51–154] 100 [56–176] 73 [49–140] 0.082
Peripheral blasts (%) 0 [0–1] 0 [0–0] 0 [0–2] 0.074
WHO 2008 0.66
CMML-1 111 (64%) 42 (62%) 69 (65%)
CMML-2 63 (36%) 26 (38%) 37 (35%)
Cytogenetic risk (n = 172) 0.11
Low 120 (70%) 52 (78%) 68 (65%)
Intermediate 22 (13%) 5 (7%) 17 (16%)
High 30 (17%) 10 (15%) 20 (19%)
Prognostic scores
CPSS (n = 172) 0.86
Low 22 (13%) 10 (15%) 12 (12%)
Intermediate-1 38 (22%) 15 (22%) 23 (22%)
Intermediate-2 88 (51%) 31 (46%) 57 (54%)
High 24 (14%) 11 (17%) 13 (12%)
GFM score (n = 174) 0.21
Low 55 (32%) 25 (37%) 30 (28%)
Intermediate 60 (34%) 23 (34%) 37 (35%)
High 59 (34%) 20 (29%) 39 (37%)
CPSS-mol (n = 133) 0.007
Low 0 0 0
Intermediate-1 1 (1%) 1 (2%) 0
Intermediate-2 40 (30%) 23 (42%) 17 (22%)
High 61 (69%) 31 (56%) 61 (78%)
Treatment before HMA 53 (39%) 25 (37%) 28 (41%) 0.73
ESA 25 (25%) 10 (23%) 15 (26%) 0.82
GCSF 2 (2%) 2 (5%) 0 0.18
Hydroxyurea 33 (24%) 15 (22%) 18 (26%) 0.69
HMA treatment
Type of HMA 68 (39%) 106 (61%)
Time from diagnosis to HMA (months) 4.2 [1.1–17.5] 1.9 [0.8–14.1] 5.1 [1.4–20.3] 0.07
Number of HMA cycles 7 [4–15] 7 [4–14] 7 [4–15] 1.00
Follow-up (months) 36.7 [25.0–66.0] 42.3 [16.2–66.2] 36.4 [25.3–66.0] 0.48
a Mann-Whitney test, Kendall's rank correlation and Fisher exact tests for continuous, ordinal and dichotomic variables, respectively.
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intermediate-1 in 22%, intermediate-2 in 51% and high risk in 14% of pa-
tients. CPSS-mol risk categorywas intermediate-1 in 1%, intermediate-2
in 30% and high-risk in 69%. Sixty-seven patients (40%) had splenomeg-
aly at onset of HMA.MedianWBCwas 15.4 × 109/L [IQR 8.6–26.0]. Fifty-
three patients (39%) had received a treatment before HMA (erythropoi-
esis stimulating agent (ESA) n=25, G-CSF n=3 and hydroxyurea n=
38 patients). Of note, 80% of CMML-1 patients treated with HMA in our
cohort fulfilled one of the following criteria: myeloproliferation (WBC
N 30 × 109/L, splenomegaly), previous ESA or hydroxyurea failure, or
CPSS intermediate-2 or high.
Sixty-eight patients (39%) received AZA and 106 patients (61%) re-
ceived DAC for a median of 7 cycles for both drugs [IQR 4–15]. Median
time from diagnosis to HMA onset was 4.2 months [IQR 1.1–17.5], and
patients were followed for a median of 36.7 months after HMA onset.
During this period, 54 patients (31%) had transformation to AML, and
17 patients (10%, median age: 58 years, range [IQR 56–65]) received
ASCT, in median 5.9 months [IQR. 3.7–9.8] after HMA onset. Median
OS was 23.0 months [IQR 11.6–58.0] and median AMLFS was
19.2 months [IQR 9.7–53.8].
Compared to AZA-treated patients, patients treated with DAC had
comparable demographics, except for a higher WBC (DAC: 17.5
× 109/L versus AZA: 13.3 × 109/L, p = .041) and non-significant trends
towards lower platelets count (DAC: 73 × 109/L versus AZA: 100
× 109/L, p = .078) and poorer cytogenetic risk (p = .11). These differ-
ences translated into a significantly poorer CPSS-mol risk (p = .007)
in DAC-treated patients. A non-significant trend to poorer OS was seen
in patients treated with DAC (median OS of 18.5 months for DAC versus31.1 months for AZA, HR= 0.73, [95% CI: 0.49–1.10], p= .13). Propen-
sity scorematching on age,WBC, platelets count, peripheral blasts, cyto-
genetic risk, time to HMA treatment, ASXL1, CBL and IDH2 mutational
statuses at HMA onset confirmed the lack of OS difference between
AZA and DAC in the 161 patients (93%) that could be successfully
matched (HR = 1.37 [95% CI: 0.61–3.10] for AZA compared to DAC, p
= .45). All further analyses were nevertheless stratified on HMA.
3.2. Mutational Landscape
Molecular information on ASXL1, from Sanger sequencing (n = 68)
or NGS (n = 106) was available for all patients, while the genotypes
of other studied genes (SRSF2, TET2, NRAS, RUNX1, CBL, U2AF1,
DNMT3A, IDH2, KRAS, SF3B1, JAK2, EZH2, IDH1, TP53) were available in
93–173 (53–99%) of cases (Supplementary Table 1). The most fre-
quently mutated genes in our cohort were SRSF2 (47%), ASXL1 (44%)
and TET2 (39%). Other frequently mutated genes included NRAS (20%),
RUNX1 (13%), CBL (12%), U2AF1 (10%) and DNMT3A (9%), as shown in
Fig. 1. There was no significant difference in the mutational spectrum
of patients studied by Sanger versus NGS (Supplementary Table 1).
Most mutations detected with NGS sequencing had a variant allele fre-
quency (VAF) above 20% (Supplementary Fig. 1), a conservative thresh-
old for the detection of somatic variants by Sanger sequencing. In
particular, considering variants detected by NGS with a VAF b 20% as
wild-type did not affect our main findings regarding survival analyses
(not shown). DAC-treated patients had less frequent IDH2 mutations
than AZA-treated patients (DAC 3% versus AZA 11%, p = .048) and a
non-significant trend towards less frequent CBL mutations (DAC 9%
Splicing genes Epigenetic regulator genes
Signaling genes Other genes
Missing data
Wild-type status






















Fig. 1.Mutational landscape of the study cohort.
177M. Duchmann et al. / EBioMedicine 31 (2018) 174–181versus AZA 17%, p= .09) andmore frequent ASXL1mutations (DAC 49%
versus AZA 37%, p = .12). Their mutational spectrum was otherwise
comparable (Supplementary Table 1). TET2 mutations were associated
with a lower cytogenetic risk. CPSS cytogenetic risk was low in 58Fig. 2. Forest plots of Odds Ratios and their 95% Confidence Intervals of (a.) Overall Response a
HMA. Forest plots of Hazard Ratios and their 95% Confidence Intervals for (c.) Overall Survival
adjusted on HMA. A significant impact on response rate is indicated in red. *p b .05. **p b .01.(88%), intermediate in 4 (6%) and high in 4 (6%) for TET2mut patients,
compared to low in 58 (57%), intermediate in 18 (18%) and high in 26
(25%) for TET2wt patients (p b .0001). Conversely, RUNX1mut patients
tended to have poorer cytogenetic risk (p = .076).nd (b.) Complete Response for each genotype in a univariate linear regression adjusted on
and (d.) AML-free Survival for each genetic or clinical variable in a univariate Cox model
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HMA
Response status according to IWG-2006 was available for 164 (94%)
patients. Overall response rate (ORR) was 52%, including complete re-
sponse (CR) in 28 (17%), partial response (PR) in 10 (6%), marrow CR
(mCR) in 18 (11%), stable disease with hematologic improvement (HI)
in 29 (18%), stable disease (SD) in 41 (25%) and progressive disease
(PD) in 38 (23%; Supplementary Table 2). Fifty (51%) and 35 (54%) pa-
tients treated with DAC and AZA achieved response (p = .75). There
was no difference in CR rate between the two HMAs (DAC 15% versus
AZA 20%; p = .53).
In univariate analysis stratified on HMA, mutations in ASXL1 pre-
dicted lower ORR (ASXL1mut 42% versus ASXL1wt 60%, p = .023).
Twenty-six (15%) patients were ASXL1mut/TET2mut, 49 (29%) were
ASXL1mut/TET2wt, 40 (24%) were ASXL1wt/TET2mut and 54 (32%) were
ASXL1wt/TET2wt. TET2mut/ASXL1wt genotype predicted higher ORR
(TET2mut/ASXL1wt 66% versus all other genotypes 47%, p = .048), while
other mutations had no effect (Fig. 2a). TET2 mutations predicted a
higher CR rate (TET2mut 26% versus TET2wt 9%, p = .005) whereas
ASXL1 mutated patients tended to achieve CR less frequently
(ASXL1mut 11% versus 22% for ASXL1wt, p = .088). An increased CR rate
was particularly apparent in patients with the TET2mut/ASXL1wt
genotype (Fig. 2b), while TET2 genotype had little influence in ASXL1mut
patients (32% for TET2mut/ASXL1wt versus 11% for all other genotypes,
p = .002).
Considering clinical variables (age, WBC, hemoglobin level, platelets
count, all analyzed as continuous variables, WHO 2008 stratification,
karyotype risk), only lower hemoglobin level (p = .001) and lower
platelets count (p = .047) predicted lower ORR. Higher WBC (p =
.038), lower hemoglobin level (p b .001) and higher cytogenetic risk
(p = .021) predicted lower CR rates while other clinical variables had
no significant impact.
In a multivariate linear regression model including type of HMA,
ASXL1 and TET2 statuses, hemoglobin level and platelets count, the pres-
ence of an ASXL1 mutation predicted a lower ORR (Odds Ratio [OR] =
0.85, 95% Confidence Interval [CI]: 0.73–0.99, p = .037) independently
of hemoglobin level (p= .001) and platelets count (p= .049). In amul-
tivariate regression model including type of HMA, TET2mut/ASXL1wt ge-
notype, WBC, hemoglobin level and cytogenetic risk, TET2mut/ASXL1wt
genotype predicted higher CR rate (OR = 1.18, [95% CI: 1.04–1.34], p
= .011), independently of the detrimental role of lower hemoglobin
level (p b .001; Table 2).
3.4. Impact of Somatic Mutations and Clinical Variables on Survival
In univariate analyses adjusted on HMA,mutations in RUNX1 (HR=
2.04, [95% CI 1.22–3.40], p= .007) and to a lesser extent CBL (HR=1.68
[95% CI: 0.95–2.98], p = .076) and ASXL1 (HR = 1.37 [95% CI:
0.93–2.00], p = .11) mutations were associated with poorer OS
(Fig. 2c). Conversely, TET2mut tended to predict prolonged OS (HR =
0.70 [95% CI: 0.46–1.05], p = .088). Mutations in SRSF2, NRAS, U2AF1,
DNMT3A, IDH2, KRAS and SF3B1 had no impact on OS. RUNX1 (HR =Table 2
Multivariate analysis for response.
Overall response Complete response
Variables OR 95% CI p= OR 95% CI p=
AZAa 1.00 [0.86–1.17] 0.96 1.01 [0.91–1.13] 0.8
ASXL1mut genotype 0.85 [0.73–0.99] 0.037 – – –
TET2mut/ASXL1wtgenotype – – – 1.18 [1.04–1.34] 0.011
Hemoglobin level 1.07 [1.03–1.11] 0.001 1.06 [1.03–1.09] b0.001
WBC (log10) – – – – – –
Platelets levelb 1.01 [1.00–1.02] 0.049 – – –
a Reference: DAC.
b For every 20 × 109/L increment.1.86; [95% CI: 1.12–3.10], p = .017) was the only gene to significantly
predict worse AMLFS (Fig. 2d). Considering the most frequently mu-
tated genes (SRSF2, TET2, ASXL1, RUNX1), there was no significant
gene–gene interaction on overall survival. The additive effect of TET2
and ASXL1 genotypes resulted in a significantly superior outcome in
TET2mut/ASXL1wt patients versus other TET2/ASXL1 genotypes (HR =
0.57, [95% CI: 0.34–0.93], p = .026). The median OS of RUNX1mut pa-
tients was 16.0 [10.3–27.6] months, compared to 24.5 [11.6–58.0]
months in RUNX1wt patients (Fig. 3). The median OS of TET2mut/ASXL1wt
patients was 32.5 [18.2–68.9] months, compared to 19.2 [10.3–42.2]
months for other genotypes. In the 155 (89%) patientswith comprehen-
sive genotyping of 8 of the top recurrentlymutated genes (SRSF2, ASXL1,
TET2, NRAS, RUNX1, CBL, IDH2 and KRAS), the number of mutated genes
had no significant impact on OS (p= .11) or on AMLFS (p= .27). Cen-
soring at ASCT did not change our main findings (not shown).
Clinical variables associatedwith poorer OS in univariate Coxmodels
adjusted on HMA were higher WBC (logWBC: HR = 2.77, [95% CI:
1.61–4.79], p b .001), lower hemoglobin level (HR = 0.90, [95% CI:
0.82–0.99], p = .039), and to a lesser extent poorer cytogenetic risk
(HR = 1.27, [95% CI: 1.00–1.60], p = .051). Time from diagnosis to
HMA onset had no impact (p = .8). Higher WBC (logWBC: HR = 2.47,
[95% CI: 1.46–4.17], p = .001), poorer cytogenetic risk (HR = 1.40,
[95% CI: 1.12–1.75], p= .004), and to a lesser extent lower hemoglobin
level (HR = 0.90, [95%CI 0.84–1.01], p= .074) and WHO-2008 stratifi-
cation (HR = 1.42, [95% CI: 0.98–2.06], p = .066) predicted shorter
AMLFS.
In a multivariate Cox analysis including RUNX1mut, CBLmut, TET2mut/
ASXL1wt genotypes together with WBC, hemoglobin level and cytoge-
netic risk, RUNX1mut (p = .011), CBLmut (p = .03) and TET2mut/ASXL1wt
(p = .05) retained their prognostic role, independently of higher WBC
(p=.005, Table 3). In a similarmodel for AMLFS, only RUNX1mutations
retained poor prognostic value (p=.048) independently of higherWBC
(p = .005) and high-risk cytogenetics (p = .018, Supplementary
Table 3).
3.5. Relevance of CMML Prognostic Scores
We next interrogated the prognostic relevance of CPSS and GFM
scores, CMML-specific prognostic scores established in all comers, in
the setting of HMA. Median OS was 68.9, 27.9, 19.2 and 16.4 months
for low, intermediate-1, intermediate-2 and high CPSS risk groups, re-
spectively (Cox model adjusted on HMA: p = .002) and 31.1, 27.6 and
15.0 months for low, intermediate and high GFM risk groups, respec-
tively (Cox model adjusted on HMA: p b .001). Their respective C-
index were 0.59 and 0.62. In particular, the GFM score, which is based
on WBC, platelets, hemoglobin and ASXL1 status identified a sub-
group of 59 (34%) high risk patients with a median OS of 15.0 months
(Fig. 4).
4. Discussion
In this study, we report on a large retrospective cohort of 174 pa-
tients the prognostic value of frequent gene mutations on the outcome
of CMML treated with HMAs. Our results demonstrate that patients
with TET2mut/ASXL1wt genotype achieve higher CR rates with a signifi-
cant survival benefit, and conversely that ASXL1 mutations predict
lower overall response rates. Our study also identifies the poor progno-
sis of RUNX1mut and CBLmut genotypes in CMML patients treated with
HMA.
A number of retrospective cohorts have investigated the prognostic
value of somatic gene mutations in CMML [8,11,14,19]. However, the
prognostic impact of gene mutations has never been investigated so
far in a large cohort of CMML patients treated by HMA. Recent studies
highlight the need to re-assess the prognostic value of a givenmutation
in specific therapeutic settings. For instance, TP53mutations are classi-
cally ascribed to a poor prognosis in myeloid malignancies including
Fig. 3.Kaplan-Meier estimates of OS according to (a.) RUNX1, (b.) ASXL1, (c.) CBL, (d.) TET2, (e.) SRSF2 and (f.) TET2mut/ASXL1wtmutational status. Results of univariate analyses stratifiedon
HMA are reported for each gene.
Table 3
Multivariate Cox models of OS adjusted on HMA.
Overall survival
Variables HR 95% CI p=
RUNX1mut genotype 2.00 [1.17–3.42] 0.011
CBLmut genotype 1.90 [1.06–3.40] 0.03
TET2mut/ASXL1wt genotype 0.60 [0.36–1.00] 0.05
WBC (log10) 2.30 [1.28–4.11] 0.005
179M. Duchmann et al. / EBioMedicine 31 (2018) 174–181MDS, yet a recent study in MDS and AML reported that TP53mutations
were associated with higher rates of response to intensive schedules of
decitabine [29]. Other predictive markers of response or prognosis have
been suggested in CMML treated with HMA, including gene expression
ormethylation profiles [3,15], but these biomarkers are difficult to stan-
dardize compared to genomic analyses, were developed in smaller co-
horts, and do not always predict survival.
The mutational spectrum of our cohort, dominated by frequent mu-
tations in ASXL1, SRSF2 and TET2, is comparable to that of other pub-
lished cohorts of CMML not selected for HMA treatment, highlighting
Fig. 4. Kaplan-Meier estimates of OS according to (a.) CPSS and (b.) GFM risk category. Results of univariate analyses stratified on HMA are reported for each score.
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the broad usage of HMAs across this landscape. However, our cohort in-
cluded only 39% of patients with TET2 mutations, a figure in the lower
range of published series [11,19], perhaps owing to the trend towards
favorable outcome of TET2mutated patients [21].
HMA indications in our cohort reflected both the US (AZA and DAC)
and European (AZA) labels of each HMA in CMML, and the inclusion
criteria of two European DAC trials [3,25]. This resulted in a higher-
risk CMML population, with 65% of patients having a CPSS risk
intermediate-2 or high and 99% of assessable patients having CPSS-
mol risk intermediate-2 or high-risk. Though the prognostic impact of
gene mutations was investigated separately in both DAC trials [3,15],
these analyses were hampered by their limited power. In the present
study, we performed a post hoc power analysis to ensure that we
could capture clinically meaningful effect (HRs N 1.5) for recurrently
mutated genes (mutations occurring in N10% of patients).
Our cohort was heterogeneous in terms of biological material and
technique used to assess somatic mutations. Mutations were studied
on sorted monocytes or on peripheral blood or bone marrow mononu-
cleated cells. However, previous studies have shown full clonal domi-
nance in the bone marrow of CMML patients compared to sorted
monocytes [12], and studies in MDS have shown that PBMCs are an ad-
equate material in these entities [17]. Samples were sequenced with ei-
ther Sanger sequencing or NGS with various gene panels. We checked
that themutational spectrum for frequentlymutated geneswere similar
between the two techniques and that exclusion of mutations found by
NGS with a VAF below 20%, which could have been overlooked by
Sanger sequencing, did not affect our results. As only 61% of patients
were assessed byNGS,wewere not able to study the impact of ancestral
versus secondary mutations in the context of HMA, a distinction that
may hold biological relevance in CMML [12,19].
In our cohort, ASXL1 mutations predicted lower ORR together with
anemia and lower platelet count. TET2 mutations did not predict ORR
in multivariate analysis, but were associated with higher CR rates in
ASXL1wildtype patients, independently of the detrimental effect of ane-
mia. These results are consistentwith previous studies inMDS [2,10,28].
We assessed responses with MDS IWG 2006 criteria [4], and it is possi-
ble that the use of the novel overlap-IWG response criteria [26], which
account for changes in the myeloproliferative component of CMML [7]
would have captured additional impact of gene mutations on response.
However, detailed data on response according to these criteria, espe-
cially spleen size and symptoms, were available in only a subset of our
patients.
In univariate analyses, RUNX1 and to a lesser extent ASXL1 and CBL
were the only frequently mutated genes associated with pooreroutcome after adjustment on the type of HMA. Conversely, TET2mut pre-
dicted prolongedOS in patientswild-type for ASXL1.We then integrated
clinical data, RUNX1mut, CBLmut and TET2mut/ASXL1wt genotypes in amul-
tivariate analysis, and found that higherWBC, RUNX1 and CBLmutations
were associated with poorer outcome, whereas TET2mut/ASXL1wt geno-
type predicted prolonged survival. Cytogenetic risk according to CPSS
was not conserved in themultivariate analysis, perhaps because it is as-
sociated in our cohort with TET2mutations, as previously reported [11].
These biomarkers are however different from those identified for sur-
vival after ASCT (namely RASmutations), which remains the only cura-
tive treatment of CMML [30].
We analyzed the prognostic relevance of CPSS and GFM scores.
Though both scores predicted to some extent overall survival, they
failed to accurately discriminate all risk groups, further strengthening
the need to carve therapy-specific prognostic scores. We could not in-
terrogate the predictive power of the recently published CPSS-mol [8],
because the mutational status of SETBP1 was only available in 32
(17%) patients and all but one evaluable patients were either
intermediate-2 or high-risk by CPSS-mol.
Our analyses focused on genesmutated in N10% of CMML cases. They
do not exclude the possibility that infrequently mutated genes have a
strong prognostic effect in patients treated with HMA. In particular,
EZH2 mutations were found in only 4% of our patients, but seemed to
bare a very poor prognosis (median OS 7.03 months for EZH2mut versus
23.0 for EZH2wt, p b .001). Finally, only analysis of prospective random-
ized trials of HMA in CMML such as the ongoing DACOTA trial
(NCT02214407) will provide information regarding the survival benefit
of HMA compared to standards of care in patients whose CMML harbor
the poor-risk genotypes identified in the present study.
In conclusion, our findings stress the need to design novel treatment
strategies in CMML with myeloproliferative features such as high WBC
or CBL mutations, and to identify druggable vulnerabilities in myeloid
neoplasms with RUNX1 mutations. Nonetheless, given the limited pre-
dictive power of current prognostic scores in CMML patients treated
with HMA, efforts to design robust biomarkers of HMA activity remains
an important area for future research in myeloid neoplasms.
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